P + LYMED

POLY MEDICURE LIMITED

kega. Office: First Floor, 12, Sant Nagar, East of Kailash, New Delhi - 110 065, Phone: 011-26481889, Fax: 011-26481894
Website: polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L74899DL1995PLC066923
STATEMENT OF STANDALONE / CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2014

₹ in lacs Standalone Consolidated Quarter ended Year ended Year ended **Particulars** 31.03.2014 31.12.2013 31.03.2013 31.03.2014 31.03.2013 31.03.2014 31.03.2013 (Unaudited) (Unaudited) (Unaudited) (Audited) (Audited) (Audited) 1 Income from operations a Net sales / income from operations 8,080.11 7,841.24 6,843.79 30,483.09 24,755.62 31,474.59 25,507.24 (net of excise duty) 468.17 103.55 188.04 67.87 750.23 750.23 468.17 b Other operating income 6,911.66 31,233.32 32,224.82 25,223.79 25,975.41 Total income from operations (net) 8.183.66 8,029.28 2 Expenses Cost of materials consumed 2,709.74 2,597.87 2,177.03 10.085.67 7.932.77 10.543.31 8.297.36 123.98 145.06 575.91 501.08 575.91 501.08 83.99 b Purchases of stock-in-trade Changes in inventories of finished goods, work-in-progress (131.87) (347.48)(110.54)(332.42)(237.96) 109.59 (59.69) and stock-in-trade d Employee benefits expense 1,329.47 1,257.17 1,110.79 4,980.36 4,023.78 5,287.48 4,227,16 372.52 339.38 299.71 1,351.06 1,182.06 1,405.50 1,304.33 e Depreciation and amortisation expense 7,915.75 2.253.12 1.841.93 8,675,50 7.761.44 8,726.00 f Other expenses 2,652,23 22.113.81 Total expenses 6,909.99 6,681.11 5,514.83 25,321.02 21,290.59 26.205.78 Profit from operations before other income, finance 1,348.17 1,396.83 5,912.30 3,933.20 6,019.04 3,861.60 1,273.67 costs and exceptional items (1-2) 3.65 2.57 106.20 36.76 105.11 29.93 61.07 4 Other income Profit from ordinary activities before finance costs 1,334.74 1,351.82 1,399.40 6,018.50 3,969.96 6,124.15 3,891.53 and exceptional items (3 + 4) 800.73 591.99 202.84 57.72 794.87 589.78 6 Finance costs 291.09 Profit from ordinary activities after finance costs but before 1,148.98 1,341.68 5,223.63 3,380.18 5,323.42 3,299,54 1.043.65 exceptional items (5 - 6) 991.46 370.80 991.46 620.66 8 Exceptional items 6,215.09 6,314.88 3,299.54 1.341.68 3,380.18 9 Profit from ordinary activities before tax (7 + 8) 1.664.31 1,519.78 526.01 413.80 416.31 1,911.88 977.26 1.911.88 977.51 10 Tax expense 2,402.92 4,403.00 2,322.03 1,138.30 1,105.98 925.37 4,303.21 11 Net Profit from ordinary activities after tax (9 - 10) 12 Extraordinary items 4,403.00 2.322.03 1.105.98 925.37 4,303.21 2,402.92 13 Net Profit for the period (11 + 12) 1.138.30 88.67 106.38 14 Share of profit / (loss) of associates 6.79 15 Loss attributable to Minority interest Net Profit / (Loss) after taxes, minority interest and share of 2,417.49 1.138.30 1,105.98 925.37 4,303,21 2,402,92 4,509.38 profit / (loss) of associates (13 + 14 + 15) 1.101.25 2.203.32 2,203.32 2,203.32 1,101.25 2.203.32 1.101.25 17 Paid-up equity share capital (Face Value of ₹ 10 each) Reserve excluding Revaluation Reserves as per balance 12,226.21 10,002.73 12,442.33 10.144.63 sheet of previous accounting year Earnings per share (before extraordinary items) (Quarterly not annualised amd yearly annualised) : 11.00 5.17 5.16 19.53 10.91 10.90 20.47 Basic (₹) 20.45 10.99 Diluted (₹) Part II - Select information for the Quarter ended March 31, 2014 PARTICULARS OF SHAREHOLDING 1 Public shareholding 11.307.773 5.649.781 11.307.773 5.649.781 11,307,773 11,307,773 5.649.781 Number of shares 51.30% 51.32% 51.30% 51.32% 51.32% 51.30% 51.32% Percentage of shareholding Promoters and Promoter Group Shareholding a) Pledged / Encumbered Number of shares Percentage of shares (as a % of the total shareholding of -promoter and promoter group) Percentage of shares (as a % of the total share capital of U _ the company) b) Non - encumbered 5,362,719 10,725,438 10,725,438 5,362,719 10,725,438 5,362,719 10,725,438 Number of shares Percentage of shares (as a % of the total shareholding of 100% 100% 100% 100% 100% 100% 100% promoter and promoter group) Percentage of shares (as a % of the total share capital of 48.68% 48.689 48.70% 48.68% 48.70% 48.68% 48.70% the company) В Investor Complaints Nil Pending at the beginning of the quarter 1 Received during the quarter 1 Disposed of during the quarter



Nil

Remaining unresolved at the end of the quarter



	Statement of Assets and Liabilities	Standalone		Consolidated	
	Particulars	As at 31.03.2014 31.03.2013		As at	
		Audited			
Α	EQUITY AND LIABILITIES	Audited	Audited	Audited	Audited
1				-	
	(a) Share capital	2,203.32	1,101.25	2,203.32	1 101 25
			10,002.73		1,101.25
	(b) Reserves and surplus	12,226.21	10,002.73	12,442.33	10,144.63
	(c) Money Received Against Share Options Sub-total - Shareholders' funds	14,429.95	11,103.98	0.42	11 245 00
	Sub-total - Shareholders Tunds	14,429.95	11,103.96	14,646.07	11,245.88
2	Minority interest	-	-	(0.24)	(0.21
3	Non-current liabilities				
	(a) Long-term borrowings	3,864.67	2,416.61	3,864.67	2,416.61
	(b) Deferred tax liabilities (net)	797.25	628.95	797.25	628.95
	(c) Other long-term liabilities	240.76	255.64	240.76	255.64
	(d) Long-term provisions	165.17	142.58	165.17	142.58
	Sub-total - Non-current liabilities	5,067.85	3,443.78	5,067.85	3,443.78
4	Current liabilities				
	(a) Short-term borrowings	1,010.13	1,344.92	1,010.13	1,344.92
	(b) Trade payables	2,883.77	2,283.89	2,970.78	2,343.20
	(c) Other current liabilities	3,806.01	2,455.98	3,849.86	2,510.55
	(d) Short-term provisions	1,050.50	560.45	1,050.50	560.45
	Sub-total - Current liabilities	8,750.41	6,645.24	8,881.27	6,759.12
	TOTAL - EQUITY AND LIABILITIES	28,248.21	21,193.00	28,594.95	21,448.57
3	ASSETS				
1	Non-current assets				
	(a) Fixed assets	14,008.95	9,715.94	14,275.76	9,983.79
	(b) Non-current investments	561.06	691.39	343.11	424.08
	(c) Long-term loans and advances	1,782.90	1,505.25	1,782.90	1,504.40
_	(d) Other non-current assets	166.90	98.53	166.90	98.53
	Sub-total - Non-current assets	16,519.81	12,011.11	16,568.67	12,010.80
	Current assets				
	(a) Inventories	3,955.73	3,287.22	4,201.04	3,536.22
	(b) Trade receivables	4,556.56	4,233.00	4,575.37	4,337.77
	(c) Cash and cash equivalents	1,378.65	72.79	1,382.53	79.82
	(d) Short-term loans and advances	1,018.73	989.01	1,043.64	879.16
	(e) Other current assets	818.73	599.87	823.70	604.80
	Sub-total - Current assets	11,728.40	9,181.89	12,026.28	9,437.77
_		20.245.51	24 402	20 504 55	24 440 77
	TOTAL - ASSETS	28,248.21	21,193.00	28,594.95	21,448.57

Notes:

- 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 15th May 2014.
- 2. The Board of Directors have recommended a dividend of 40% (₹ 4 per equity share), subject to approval of shareholders.
- 3. The figures of last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended 31st March and the unaudited published year-to-date figures upto the third quarter ended 31st December.
- 4. The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- 5. During the year ended 31st March 2014, the Company has issued 11012500 equity shares of ₹ 10 each as Bonus Share, accordingly paid up equity share capital of the company has increased by ₹ 1101.25 lacs. EPS for the previous periods have been restated for the comparison purposes.
- 6. The company has also issued 8211 number of equity shares to eligible employees under ESOP scheme 2011. Further 1685 number of options were exercised and are pending for allotment as on 31st March 2014 and is disclosed as money received against share options.
- 7. In view of option allowed by the Ministry of Corporate Affairs vide its notification dated 29th December 2011 on AS 11, the exchange differences arising on reporting of long term foreign currency monetary items at rates different from those at which they were initially recorded have been accumulated in a "Foreign Currency Monetary Items Translation Difference Account" to be amortised over the balance period of such long term assets or liabilities. Pursuant to such adoption, a sum of ₹ 128.06 lacs is remained to be amortised over the balance period of such assets or liabilities.
- 8. Exceptional items in statement of profit and loss represents one time income of ₹ 991.46 lacs from one of its customer towards settlement of a contract.
- 9. The company has made a provision of ₹ 130.33 lacs on account of diminution in the value of investment in subsidiary company and has been included in other expenses of stand alone results.
- 10. The consolidated Financial Statement has been prepared in accordance with AS- 21 " Consolidated Financial Statements" and AS-23 " Accounting for investment in Associates in Consolidated financial Statements".
- 11. The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

Place : New Delhi Date : 15.05.2014 GR & ASSOCIATION OF READ NO.

By order of the Board Himanshu Baid

Managing Director